BioSpace News Archive

Remix Therapeutics announced that its management team will host one-on-one meetings with investors at the Jefferies Healthcare Conference taking place on Tuesday, June 4, 2024 in New York City.

Cartography Biosciences, Inc., announced that it has entered into a strategic collaboration agreement with Gilead Sciences, Inc., to discover and develop therapies for patients with triple-negative breast cancer and the most common form of non-small cell lung cancer, adenocarcinoma.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens.

Stevanato Group S.p.A. announced today that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer.

Mind Medicine (MindMed) Inc. announced today that members of the Company’s management team will participate in the following conferences.

Numab Therapeutics AG announced that the Company has entered into a definitive agreement whereby Johnson & Johnson acquires Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab to be spun-off to Numab’s shareholders.

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc. today announced several key updates on its National Institutes of Health (NIH)-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8® compassionate use in ALS.

Apogee Therapeutics, Inc. today announced that Lisa Bollinger, MD, has been appointed to the company’s board of directors.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee.

Dyne Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $31.00 per share.